University of Kentucky Research Foundation Patent applications |
Patent application number | Title | Published |
20160100548 | ALTERATION OF TOBACCO ALKALOID CONTENT THROUGH MODIFICATION OF SPECIFIC CYTOCHROME P450 GENES - Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in | 04-14-2016 |
20160032256 | Cytochrome P450S and Uses Thereof - The invention features isolated cytochrome P450 polypeptides and nucleic acid molecules, as well as expression vectors and transgenic plants containing these molecules. In addition, the invention features uses of such molecules in methods of increasing the level of resistance against a disease caused by a plant pathogen in a transgenic plant, in methods for producing altered compounds, for example, hydroxylated compounds, and in methods of producing isoprenoid compounds. | 02-04-2016 |
20160024530 | Cytochrome P450S and Uses Thereof - The invention features isolated cytochrome P450 polypeptides and nucleic acid molecules, as well as expression vectors and transgenic plants containing these molecules. In addition, the invention features uses of such molecules in methods of increasing the level of resistance against a disease caused by a plant pathogen in a transgenic plant, in methods for producing altered compounds, for example, hydroxylated compounds, and in methods of producing isoprenoid compounds. | 01-28-2016 |
20150327892 | TEMPORARY FRACTURE STABILIZATION DEVICE - A temporary fracture stabilization device includes a first intramedullary fixation rod, a second intramedullary fixation rod, a first extramedullary connector, a second extramedullary connector and a fastener. A field kit for temporary fracture stabilization is also disclosed. | 11-19-2015 |
20150297550 | SUSTAINED RELEASE OF TOPICAL ANESTHETICS - A composition and method to alleviate oral mucosal discomfort and irritation in an orthodontic patient. A wax matrix containing less that 15% analgesic/anesthetic agent such as benzocaine and excipients enhanced and extended release of the analgesic/anesthetic agent compared to known art formulations. The composition exhibited desirable aesthetic properties, was easy to apply, and the relatively lower concentration of active agent provided enhanced safety. | 10-22-2015 |
20150208059 | System and Method for 3D Imaging using Structured Light Illumination - A biometrics system captures and processes a handprint image using a structured light illumination to create a 2D representation equivalent of a rolled inked handprint. A processing unit calculates 3D coordinates of the hand from the plurality of images and maps the 3D coordinates to a 2D flat surface to create a 2D representation equivalent of a rolled inked handprint. | 07-23-2015 |
20150132315 | METHODS TO IMPAIR HEMATOLOGIC CANCER PROGENITOR CELLS AND COMPOUNDS RELATED THERETO - Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3Rα or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieties such as, for example, radioisotopes or chemotherapeutics. | 05-14-2015 |
20140342357 | METHODS OF INHIBITING ALU RNA AND THERAPEUTIC USES THEREOF - The presently-disclosed subject matter includes methods of identifying an Alu RNA inhibitor, and methods and compositions for inhibiting Alu RNA. Methods and compositions can be used for the treatment of geographic atrophy and other conditions of interest. | 11-20-2014 |
20140329453 | BLOWING CURTAIN FACE VENTILATION SYSTEM FOR EXTENDED CUT MINING USING PASSIVE REGULATOR - A ventilation system for an underground mine includes a blowing curtain, a passive regulator in a shape of an airfoil and an airflow ventilation source. The passive regulator is positioned in the air path adjacent a discharge end of the blowing curtain. | 11-06-2014 |
20140311386 | HYBRID CEMENT CLINKER AND CEMENT MADE FROM THAT CLINKER - A hybrid cement clinker incorporates specific ranges of clinker phases and falls within specific modulus values as set forth and described in this document. | 10-23-2014 |
20140295311 | FLOW BATTERY - An electrolyte system for a flow battery has an anolyte including [Fe(CN) | 10-02-2014 |
20140262745 | ENHANCEMENT OF BINDING CHARACTERISTICS FOR PRODUCTION OF AN AGGLOMERATED PRODUCT - A method is provided for preparing a product from a precursor material. The method includes the steps of (a) mixing a particulate material and a binder to form a precursor material and (b) irradiating that precursor material with microwave radiation so as to activate the binder and form the product. | 09-18-2014 |
20140260470 | NITROGEN FERTILIZER COMPOSITION AND METHOD TO IMPROVE DETECTION AND LESSEN THE EXPLOSIVE POTENTIAL OF NITROGEN-BASED FERTILIZERS - A nitrogen fertilizer composition includes urea and a nitrate-based fertilizer such as ammonium nitrate, calcium ammonium nitrate and mixtures of ammonium nitrate and calcium ammonium in which the urea and total nitrogen are at concentrations of 20 percent by weight or greater and the concentration of ammonium nitrate is at 30 percent or greater by weight. One or both of the urea and nitrate-based fertilizer are coated with an agriculturally compatible material. The fertilizer composition provides significant nitrate nitrogen for legitimate agricultural use yet is not amenable to the production of an explosive by crushing or by aqueous extraction. A pleasant smelling odorant is added to the composition to facilitate detection. | 09-18-2014 |
20140249161 | STILBENE ANALOGS AND METHODS OF TREATING CANCER - Stilbene analogs and pharmaceutical compositions that are useful for the treatment of various cancers, including without limitation, colorectal cancer (CRC) and breast cancer are disclosed. The halogenated stilbene analogs include nitrogen heteroaryl groups and/or amino groups on the stilbene ring. | 09-04-2014 |
20140208753 | METHOD FOR ENERGY STORAGE TO UTILIZE INTERMITTENT RENEWABLE ENERGY AND LOW-VALUE ELECTRICITY FOR CO2 CAPTURE AND UTILIZATION - A power plant includes a boiler, a steam turbine, a generator driven by that steam turbine, a condenser, a post combustion processing system and an energy storage system including at least one electrochemical cell to store excess electrical energy generated by the generator during period valley demand and release thermal energy for power plant operations at other times. | 07-31-2014 |
20140178309 | PROTECTION OF CELLS FROM ALU-RNA-INDUCED DEGENERATION AND INHIBITORS FOR PROTECTING CELLS - A method of protecting a cell includes inhibiting an inflammasome, MyD88, IL-18, VDAC1, VDAC2, caspase-8, and/or NFκB of the cell. Administering an inhibitor of MyD88, IL-18, VDAC1, VDAC2, caspase-8, and/or NFκB can protect the cell from Alu-RNA-induced degeneration. Protecting a cell, such as an retinal pigment epithelium (RPE), can be therapeutically useful in the context of age-related macular degeneration and geographic atrophy. | 06-26-2014 |
20140161961 | SOY PRODUCTS WITH REDUCED LEVELS OF SULFITE, FREE RADICALS AND METHANETHIOL - Soy products or compositions are treated with a food grade iodate compound or a cystine compound to reduce levels of methanethiol, sulfites and sulfite free-radicals, sulfate free radicals and other free radicals generated from sulfite free radicals in the soy products or compositions by 1% to 95%. | 06-12-2014 |
20140148393 | Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation - The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies. | 05-29-2014 |
20140106375 | Secreted Tumor-Associated Cytochrome as a Blood-Based Biomarker for Cancer - Disclosed herein are methods for detecting Pgrmc1 in bodily fluids, e.g., blood, plasma and serum, wherein detection of Pgrmc1 is a biomarker for the presence of cancer, e.g., lung cancer or head or neck cancer. Pgrmc1 levels in bodily fluids may be used to predict patient prognosis, e.g., survival and response to therapy. | 04-17-2014 |
20140104754 | CARBON PARTICLES - A composition generally includes carbon particles. The particles are prepared by dissolving a carbohydrate-based precursor in water to form a precursor solution and placing the precursor solution in a pressure vessel. The precursor solution is placed in a pressure vessel. The pressure vessel is heated to a reaction temperature to form carbon particles. The carbon particles are subjected to a chemical activation and a physical activation. The composition includes, by weight, about 5% to about 30% oxygen. | 04-17-2014 |
20140080866 | Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors - Provided are tris-quaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse and/or gastrointestinal tract disorders. | 03-20-2014 |
20140080859 | Bis-Quaternary Ammonium Cyclophane Compounds that Interact with Neuronal Nicotinic Acetylcholine Receptors - Provided are bis-quaternary ammonium cyclophane compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders. | 03-20-2014 |
20140066329 | LUNG CANCER DIAGNOSTIC ASSAY - A method for selecting a person at risk for lung cancer to undergo radiographic testing is provided. The method provides for the identification of markers for lung cancer in a population of patients that have not previously diagnosed with the disease. The markers identify autoantibodies present in a fluid sample of a patient who may not show other symptoms of lung cancer. | 03-06-2014 |
20140027677 | CARBON PARTICLES - A composition generally includes carbon particles. The particles are prepared by dissolving a carbohydrate-based precursor in water to form a precursor solution and placing the precursor solution in a pressure vessel. The precursor solution is placed in a pressure vessel. The pressure vessel is heated to a reaction temperature to form carbon particles. The carbon particles are subjected to a chemical activation and a physical activation. The composition includes, by weight, about 5% to about 30% oxygen. | 01-30-2014 |
20140011836 | METHOD OF TREATING NEUROPATHIC PAIN - Provided are methods for using bis-quaternary ammonium compounds to treat inflammatory pain, neuropathic pain and nociceptive pain. | 01-09-2014 |
20130321585 | System and Method for 3D Imaging using Structured Light Illumination - A biometrics system captures and processes a handprint image using a structured light illumination to create a 2D representation equivalent of a rolled inked handprint. A processing unit calculates 3D coordinates of the hand from the plurality of images and maps the 3D coordinates to a 2D flat surface to create a 2D representation equivalent of a rolled inked handprint. | 12-05-2013 |
20130231366 | Use of a Novel Alpha-7 Nachr Antagonist to Suppress Pathogenic Signal Transduction in Cancer and Aids - This application provides a method for the use of select quaternary ammonium antagonists to alpha-7 nAChR for the treatment of cancer and HIV and AIDS. | 09-05-2013 |
20130198896 | Systems and methods for the production of linear and branched-chain hydrocarbons - A system and method is provided for producing linear and branched hydrocarbons and in particular triterpenes in plant cells. The system and method includes a transformed plant cells with an isolated nucleic acid encoding a farnesyl diphosphate synthase (FPS) and with an isolated nucleic acid encoding a triterpene synthase. | 08-01-2013 |
20130164765 | METHOD AND SYSTEM FOR DIAGNOSIS OF LAWSONIA INTRACELLULARIS - A method, system, and kit are provided for diagnosing | 06-27-2013 |
20130136318 | System and method for 3D imaging using structured light illumination - A biometrics system captures and processes a handprint image using a structured light illumination to create a 2D representation equivalent of a rolled inked handprint. A processing unit calculates 3D coordinates of the hand from the plurality of images and maps the 3D coordinates to a 2D flat surface to create a 2D representation equivalent of a rolled inked handprint. | 05-30-2013 |
20130123188 | METHODS FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE (AD) USING THE MOLECULES THAT STABILIZE INTRACELLULAR CALCIUM (Ca2+) - The subject technology relates, in part, to a method of treating Alzheimer's Disease (AD), early-stage AD, elevated risk of AD, mild cognitive impairment (MCI), or other forms of age-related cognitive decline in a subject in need thereof by administering to the subject a molecule that promotes calcium-release stabilization in ryanodine receptors (RyRs) and/or inosital triphosphate receptors (InsP3Rs) in brain cells. Diagnostic methods using calcium-release stabilizing immunophilins, junctophilins or calmodulin are also disclosed. | 05-16-2013 |
20130122063 | Nanotubes as Mitochondrial Uncouplers - A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca | 05-16-2013 |
20130101632 | NANOPARTICULATE FORMULATIONS OF MITHRAMYCIN OR MITHRAMYCIN ANALOGUES FOR TREATING CANCER - Methods and formulations for improving therapeutic potential of mithramycin (MTM) or MTM analogues are disclosed. For example, in certain aspects, methods for preparing a composition containing MTM or an MTM analogue nanoparticulate formulation and uses thereof are described. Furthermore, methods for delivering MTM or MTM analogues are disclosed. | 04-25-2013 |
20130065830 | Dopamine Neuron Stimulating Peptide-11 Protection From Complex 1 Mitochondrial Inhibitors - The present invention relates to the use of novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), for treating brain diseases and injuries that result in dopaminergic deficiencies and mitochodrial dysfunction, e.g., reduced complex I enzyme activity. | 03-14-2013 |
20130007909 | EARLY FLOWERING CHIA AND USES THEREOF - The invention relates to early flowering Chia ( | 01-03-2013 |
20120269404 | System and method for 3D imaging using structured light illumination - A biometrics system captures and processes a handprint image using a structured light illumination to create a 2D representation equivalent of a rolled inked handprint. A processing unit calculates 3D coordinates of the hand from the plurality of images and maps the 3D coordinates to a 2D flat surface to create a 2D representation equivalent of a rolled inked handprint. | 10-25-2012 |
20120214728 | EX VIVO AND IN VIVO METHODS AND RELATED COMPOSITIONS FOR REGENERATING HEMATOPOIETIC STEM CELL POPULATIONS - Various embodiments provide methods and related compositions for increasing the population size of hematopoietic stem cells (HSCs) in patients that may benefit from reconstitution of stem cells and/or differentiated cells of the blood lineage. The present methods enable the production of HSCs ex vivo and in vivo by reducing latexin expression and/or latexin activity within HSC exposed to various antagonists. Inhibition of latexin expression and/or latexin activity by various antagonists can promote HSC proliferation and/or inhibit HSC apoptosis. Antagonists that can reduce latexin expression and/or latexin activity can be utilized to regenerate endogenous HSCs within patients affected with disorders, diseases, cancers, or therapies for such conditions, that result in the depletion or reduction in HSCs. | 08-23-2012 |
20120202892 | Cannabinoid-Containing Compositions and Methods for Their Use - This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the area of the injury or the area affected by the disease condition, e.g., an arthritic joint. The cannabinoid-containing composition is preferably a pharmaceutically acceptable gel containing a therapeutically effective amount of a cannabinoid sufficient to alleviate the symptoms associate with the injury or disease condition. | 08-09-2012 |
20120202891 | Cannabinoid-Containing Compositions and Methods for Their Use - This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the area of the injury or the area affected by the disease condition, e.g., an arthritic joint. The cannabinoid-containing composition is preferably a pharmaceutically acceptable gel containing a therapeutically effective amount of a cannabinoid sufficient to alleviate the symptoms associate with the injury or disease condition. | 08-09-2012 |
20120122943 | Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents - Melampomagnolide B is disclosed as a new antileukemic sesquiterpene. A biotin-conjugated derivative of melampomagnolide B was prepared to elucidate its mechanism of action. Prodrugs of Melampomagnolide B are disclosed. | 05-17-2012 |
20120118308 | ALTERATION OF TOBACCO ALKALOID CONTENT THROUGH MODIFICATION OF SPECIFIC CYTOCHROME P450 GENES - Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in | 05-17-2012 |
20120117933 | ALTERATION OF TOBACCO ALKALOID CONTENT THROUGH MODIFICATION OF SPECIFIC CYTOCHROME P450 GENES - Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in | 05-17-2012 |
20120064010 | CCR3 and its Ligands Are Therapeutic and Diagnostic Targets for Neovascular Age-Related Macular Degeneration - The results presented herein demonstrate the specific expression of CCR3 in CNV endothelial cells in humans with AMD, and despite the expression of its ligands, eotaxin-1, -2, and -3, neither eosinophils nor mast cells are present in human CNV. The genetic or pharmacological targeting of CCR3 or eotaxins as disclosed herein inhibited injury-induced CNV in mice. CNV suppression by CCR3 blockade was due to direct inhibition of endothelial cell proliferation, and was uncoupled from inflammation as it occurred in mice lacking eosinophils or mast cells and was independent of macrophage and neutrophil recruitment. CCR3 blockade was more effective at reducing CNV than vascular endothelial growth factor-A (VEGF-A) neutralization, which is currently in clinical use, and, unlike VEGF-A blockade, not toxic to the mouse retina. In vivo imaging with CCR3-targeting quantum dots located spontaneous CNV invisible to standard fluorescein angiography in mice before retinal invasion. CCR3 targeting is useful in reducing vision loss due to AMD through early detection and therapeutic angioinhibition. | 03-15-2012 |
20110268723 | CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration - Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis. | 11-03-2011 |
20110263518 | D-Tagatose-Based Compositions and Methods for Preventing and Treating Atherosclerosis, Metabolic Syndrome, and Symptoms Thereof - Pharmaceutical compositions including D-tagatose along with a stilbene or stilbenoid component, or a salt or derivative thereof. Methods of prophylaxis and therapy by administering to a mammal a pharmaceutically effective amount of D-tagatose, optionally in combination with a stilbene or stilbenoid component, or a salt or derivative thereof to prevent or treat atherosclerosis, the metabolic syndrome, obesity, or diabetes. | 10-27-2011 |
20110178025 | Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation - The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies. | 07-21-2011 |
20110174322 | ALTERATION OF TOBACCO ALKALOID CONTENT THROUGH MODIFICATION OF SPECIFIC CYTOCHROME P450 GENES - Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in | 07-21-2011 |
20110166177 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS - Provided are methods for using bis-quaternary ammonium compounds to treat inflammatory pain, neuropathic pain and nociceptive pain. | 07-07-2011 |
20110160694 | Nanotubes as Mitochondrial Uncouplers - A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca | 06-30-2011 |
20110142938 | Nanotubes as Mitochondrial Uncouplers - A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca | 06-16-2011 |
20110105556 | TRIS-QUARTERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS - Provided are tris-quaternary ammonium compounds which are modulators of nicotinic acetylocholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse and or gastrointestinal tract disorders. | 05-05-2011 |
20110104724 | BIOMARKERS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE - A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and/or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and/or serotransferrin protein; | 05-05-2011 |
20110097390 | Ultra-Small RNAs as Toll-Like Receptor-3 Antagonists - Provided are methods and compositions for the treatment or prevention of macular degeneration or other diseases or disorders associated with activation of TLR | 04-28-2011 |
20100266540 | DRUG CLASS FOR THE TREATMENT OF CANCER - Compositions, methods, and combination therapies for the treatment of cancers, including lymphomas, leukemias, melanomas, lung cancer, and metastatic disease, are provided. Specifically, compositions comprising ligands to Pgrmc1 are disclosed for use in treating and inhibiting tumor growth and progression and inhibition of metastases. The compositions and methods using these ligands can be used alone or in combination with other reagents and cancer treatment modalities. | 10-21-2010 |
20100222377 | BIS-QUATERNARY AMMONIUM CYCLOPHANE COMPOUNDS THAT INTERACT WITH NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS - Provided are bis-quaternary ammonium cyclophane compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders. | 09-02-2010 |
20100216847 | NORNICOTINE FOR THE TREATMENT OF PAIN - This invention relates to the use of R(+)-, S(−)- or racemic nornicotine for the treatment of pain. | 08-26-2010 |
20100184692 | Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation - The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies. | 07-22-2010 |
20100183585 | METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTASES THROUGH THE MODULATION OF LATEXIN - The present invention relates to methods for treating cancers and metastatic diseases by modulating latexin expression and/or latexin activity. | 07-22-2010 |
20100179186 | USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS - This application provides a method for the use of select quaternary ammonium antagonists to alpha-7 nAChR for the treatment of cancer and HIV and AIDS. | 07-15-2010 |
20100173937 | USE OF TETRAKIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS - Provided are methods of modulating, treating, reversing and/or preventing pain using tetrakis quaternary ammonium compounds, especially regarding pain of central and/or peripheral origin and/or pain which is nociceptive, neuropathic, somatic, visceral, and/or inflammatory in nature. | 07-08-2010 |
20100152237 | BIS-PYRINDINO CONTAINING COMPOUNDS FOR THE USE IN THE TREATMENT OF CNS PATHOLOGIES - N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter. | 06-17-2010 |
20100120857 | USE OF TRIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS - Provided are tris-quaternary ammonium compounds which are modulators of nociception and pain. | 05-13-2010 |
20100113511 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors - Provided are monoquaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders. | 05-06-2010 |
20100105067 | BIOMARKERS FOR OVARIAN CANCER - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer, ovarian cancer of low malignant potential, benign ovarian disease or other malignant condition. The biomarkers can be detected by SELDI mass spectrometry. | 04-29-2010 |
20100098274 | METHOD AND SYSTEM FOR CREATING THREE-DIMENSIONAL SPATIAL AUDIO - A system and method for rendering a virtual sound source using a plurality of speakers in an arbitrary arrangement includes expanding a wave field of the virtual sound source and a composite wave field generated by the plurality of speakers into multi-pole expansions, and equating the multi-pole expansions to each other to form a continuous equation. A set of constraints is applied to the continuous equation that minimize an error in a sweet spot region resulting in a linear system of equations. The linear system of equations is solved using singular-value decomposition to arrive at a pseudo-inverse representing a multi-dimensional transfer function between the virtual sound source and the plurality of speakers. The multi-dimensional transfer function is then applied to a signal of the virtual sound source to render the virtual sound source in the sweet spot region using the plurality of speakers in the arbitrary arrangement. | 04-22-2010 |
20100087657 | ENANTIOSELECTIVE SYNTHESIS OF (+) AND (-)-2-[1-(2,6-DICHLOROPHENOXY)-ETHYL]-1,3-DIAZACYCLOPENT-2-3ENE - This application provides a method for the enantioselective synthesis of (+) and (−) lofexidine or 2-[1-(2,6)-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene. | 04-08-2010 |
20100086973 | GLYCOSYLATE DERIVATIVES OF MITHRAMYCIN, METHOD OF PREPARATION AND USES THEREOF - The present invention provides compounds characterized by the formula (I), where each of the substituent radicals is described in the specification. The invention also describes the use of said compounds in the treatment of various diseases, including: cancer or tumoral processes in general, Paget's disease, hypercalcaemia, hypercalciuria and neurological diseases (inter alia, Parkinson's, Alzheimer's, Huntington's). | 04-08-2010 |
20100081678 | INDOLE COMPOUNDS AND THEIR USE AS RADIATION SENSITIZING AGENTS AND CHEMOTHERAPEUTIC AGENTS - Indole derivatives that are useful in the treatment of cancer as a chemotherapeutic agent or radiosensitizing agent. | 04-01-2010 |
20100069432 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors - Provided are bis-quaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders. | 03-18-2010 |
20100041120 | Botryoccocus braunii Triterpene Synthase Proteins and Nucleic Acid Molecules, and Methods for Their Use - This application relates to the functional identification and characterization of a nucleic acid molecule encoding a triterpene synthase, in particular botryococcene synthase. Also described are host cells comprising the nucleic acid molecules of this invention, proteins encoded by the nucleic acid molecules and methods for using the nucleic acid molecules, transformed hosts and encoded proteins to produce high levels of triterpene hydrocarbons. | 02-18-2010 |
20100035820 | AMIDATED DOPAMINE NEURON STIMULATING PEPTIDES FOR CNS DOPAMINERGIC UPREGULATION - The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies. | 02-11-2010 |
20100031990 | Cascaded Photovoltaic and Thermophotovoltaic Energy Conversion Apparatus with Near-Field Radiation Transfer Enhancement at Nanoscale Gaps - A cascaded photovoltaic/thermophotovoltaic energy conversion apparatus, a cascaded thermophotovoltaic energy conversion apparatus, and a method for forming the apparatuses are provided. The cascaded photovoltaic/thermophotovoltauc apparatus includes a photovoltaic device that receives solar radiation on an upper surface thereof and produces a first electric current output and a thermal radiation output, and a thermophotovoltaic device disposed a predetermined distance below a lower surface of the photovoltaic device, the thermophotovoltaic device receiving the thermal radiation output and converting the received thermal radiation output into a second electric current output. The cascaded thermophotovoltaic apparatus includes a radiator maintained at constant temperature via an external heat input on its upper surface and produces a thermal radiation output, and a thermophotovoltaic device disposed a predetermined distance below a lower surface of the radiator, the thermophotovoltaic device receiving the thermal radiation output and converting the received thermal radiation output into a first electric current output. | 02-11-2010 |
20100009423 | B. BRAUNII, RACE B GENE FOR A TRITERPENE METHYLTRANSFERASE ENZYME AND USES THEREOF - Provided is an isolated polypeptide having triterpene methyltransferase activity. Also provided is an isolated nucleic acid molecule that encodes the triterpene methyltransferase polypeptides; a vector comprising the nucleic acid molecules that encode the triterpene methyltransferase polypeptides; and a host cell(s) transfected with the aforementioned nucleic acid molecule or vector. In another aspect, a method of producing a methylated triterpene is provided. The method comprises providing a metabolizable carbon source to a host cell transfected with a nucleic acid molecule that encodes a triterpene methyltransferase under conditions sufficient for production of a methylated triterpene. The method optionally further comprises isolating the methylated triterpene produced by the host cell. | 01-14-2010 |
20090281038 | Phylloplanins Inhibition of Microbial Growth on Organic Materials - The present invention relates to plant proteins produced by a plant's epidermal layer that contribute to the innate pest/disease resistance of the plant (“phylloplanins’), compositions comprising the phylloplanins and methods of using the them. In particular the methods relate to inhibiting or prevent microbial, e.g., fungal or bacterial, growth on a subject, organism or surface, particularly inhibiting or preventing spoilage of food products due to microbial infection and growth. The invention also relates to transformed host cells that produce the phylloplanins, and to transgenic plants producing phylloplanins conferring increased resistance to microbial infections/growth. | 11-12-2009 |
20090263804 | Biomarkers for aging - A statistical and functional correlation strategy to identify changes in cellular pathways specifically linked to impaired cognitive function with aging. Analyses using the strategy identified multiple groups of genes expressed in the hippocampi of mammals, where the genes were expressed at different levels for several ages. The aging changes in expression began before mid-life. Many of the genes were involved in specific neuronal and glial pathways with previously unrecognized relationships to aging and/or cognitive decline. These identified genes and the proteins they encode can be used as novel biomarkers of brain aging and as targets for developing treatment methods against age-related cognitive decline, Alzheimer's Disease and Parkinson's Disease. | 10-22-2009 |
20090260091 | Methods and animal model for analyzing age-related macular degeneration - Methods for testing candidate drugs for treatment of age-related macular degeneration are provided. Ccl2-deficient, and Ccr2-deficient mice are used to determine the effect of candidate drugs and treatments on development of age-related macular degeneration. Also provided is a Ccl2-deficient, Ccr2-deficient dual knockout mouse, which is a useful animal model for age-related macular degeneration. | 10-15-2009 |
20090238793 | TOLL LIKE RECEPTOR (TLR) STIMULATION FOR OCULAR ANGIOGENESIS AND MACULAR DEGENERATION - Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of stimulators of the TLR3 and TLR7 receptors, Trif or of IL-10 and IL-12 inhibits ocular angiogenesis. Furthermore, all siRNAs (both targeted and non-targeted) can inhibit ocular angiogenesis. | 09-24-2009 |
20090215667 | Utility of phylloplanins as antibiotics, selective fungicides and for enhancing microbial resistance in plants - The present invention relates to plant proteins produced by a plant's epidermal layer that contribute to the innate pest/disease resistance of the plant (“phylloplanins”), compositions comprising the phylloplanins and methods of using them. In particular the methods relate to inhibiting or preventing microbial, e.g., fungal or bacterial, growth on a subject, organism or surface by administering a phylloplanin. The invention also relates to transformed host cells that produce phylloplanins, and to transgenic plants producing phylloplanins conferring increased resistance to microbial infections/growth. | 08-27-2009 |
20090205072 | ALTERATION OF TOBACCO ALKALOID CONTENT THROUGH MODIFICATION OF SPECIFIC CYTOCHROME P450 GENES - Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in | 08-13-2009 |
20090202510 | ALTERED SUMOYLATION OF LAMIN A PROTEIN ASSOCIATED WITH DILATED CARDIOMYOPATHY - This invention relates to methods of diagnosing dilated cardiomyopathy using analysis of the lamin A protein and sumylation of same, as well as methods for treating dilated cardiomyopathy, comprising enhancing the sumoylation of the lamin A protein in a subject in need thereof. | 08-13-2009 |
20090196918 | Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions - Provided is a liposome comprising a hydrophobic lactone drug and a cyclodextrin, wherein the liposome has an intraliposomal pH and cyclodextrin concentration such that upon administration of the liposome to a subject, the liposome exhibits a uniform release profile of the hydrophobic lactone drug. Also provided is a method of administering a hydrophobic lactone drug to a subject in need thereof. The method comprises administering a liposome to the subject in need, wherein the liposome comprises the hydrophobic lactone drug and a cyclodextrin. The liposome has an intraliposomal pH and cyclodextrin concentration such that upon administration of the liposome to the subject, the liposome exhibits a uniform release profile of the hydrophobic lactone drug. | 08-06-2009 |
20090196917 | Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions - Disclosed herein is a liposomal formulation that comprises a liposome and a liquid carrier. In the liposomal formulation, the liposome comprises a hydrophobic lactone drug and has an intraliposomal metal ion concentration higher than the metal ion concentration of the liquid carrier. Also disclosed herein is a method for active loading of a hydrophobic lactone drug into a liposome. The method includes preparing a liposome in the presence of a metal salt solution, an acid form of a counterion of the metal salt being membrane permeable, such that the liposome preparation contains entrapped metal ion. The method further includes forming a liposome with high intraliposomal pH by separating extravesicular metal salt solution from the liposome by exposing the liposome to a metal salt-free solution, resulting in diffusion of the acid form of the counterion out of the liposome and formation of an intraliposomal pH higher than that of the metal salt-free solution. The method also includes exposing the liposome with high intraliposomal pH to an isoosmolal solution containing a hydrophobic lactone drug, the isoosmolal solution having a pH lower than the intraliposomal pH, such that the hydrophobic lactone drug accumulates in the liposome predominantly in its ring-opened form. | 08-06-2009 |
20090181445 | Crystallization and Structure of a Plant Peptide Deformylase - This invention relates to the crystal structure of a plant peptide deformylase polypeptide and methods of using the structure to design compounds that modulate the activity of the polypeptide. | 07-16-2009 |
20090170865 | Treatment of Prostate Cancer with Angiogenesis-Targeting Quinazoline-Based Anti-Cancer Compounds - Provided is a method of inhibiting the growth of prostate cancer cells comprising administering an effective amount of DZ-50 (2-[4-biphenyl-4-sulfonyl)-piperazin-1-yl]-6,7-diisopropoxyquinazolin-4-yl-amine) to a patient in need thereof. In another aspect, a method is provided for inhibiting the initiation of prostate cancer comprising administering an effective amount of DZ-50 to a patient in need thereof. In yet another aspect, a method is provided for inhibiting the formation of a prostate tumor-derived metastatic lesion comprising administering an effective amount of DZ-50 to a patient in need thereof. In any of the aforementioned methods, a quinazoline-based drug which induces apoptosis of a prostate cancer cell may be coadministered with DZ-50. Also provided is a composition comprising DZ-50, a quinazoline-based drug which induces apoptosis of a prostate cancer cell, and a pharmaceutically acceptable carrier. | 07-02-2009 |
20090143424 | TETRAKIS-QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACTEYLCHOLINE RECEPTORS - Provided are tetrakis-quaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders. | 06-04-2009 |
20090133133 | Transgenic Mice for Bioassay of Prions from Deer and Elk with Chronic Wasting Disease - The invention relates to the use of transgenic constructs to produce animal models for the study of chronic wasting disease. | 05-21-2009 |
20090123375 | CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration - Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis. | 05-14-2009 |
20090117054 | SUBLINGUAL SPRAY FOR THE TREATMENT OF PAIN - This invention relates to a spray for sublingual administration, used in the treatment and management of pain, especially acute pain. Also provided are methods of treatment and management of pain, a metered dosage system for administration of the spray, and combination therapies. | 05-07-2009 |
20090070901 | Modified rubisco large subunit n-methyltransferase useful for targeting molecules to the active-site vicinity of ribulose-1, 5-bisphosphate - The present invention generally relates to a modified Rubisco large subunit | 03-12-2009 |
20090028831 | STEM CELL REGULATOR, COMPOSITIONS AND METHODS OF USE - The disclosure provides methods and compositions comprising Slit2 agonists and antagonists useful for modulating hematopoietic stem cell (HSC) proliferation and growth. In some aspects, the disclosure provides methods and compositions for stimulating HSC proliferation in vivo, ex vivo, or in vitro. In other aspects, the disclosure provides methods and compositions for inhibiting HSC proliferation. | 01-29-2009 |
20090017102 | Enhancing transdermal delivery of opiod antagonists and agonistis using codrugs links to bupropion or hydroxybupropion - The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a significant increase in the transdermal flux across human skin, as compared to the basic opioid antagonist or opioid agonist. | 01-15-2009 |
20080299130 | Methods And Compositions For The Treatment Of Ocular Neovascularization - The invention relates to compositions and methods for the treatment or prevention of ocular neovascularization by reducing macrophage infiltration into the eye. The compositions of the invention include an antagonist of MCP-1 and/or CCR2 that blocks MCP-1 binding to or activation of CCR2y. | 12-04-2008 |
20080287490 | Bis-pyridino containing compounds for the use in the treatment of CNS pathologies - N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter. | 11-20-2008 |
20080202541 | Alteration of tobacco alkaloid content through modification of specific cytochrome P450 genes - Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in | 08-28-2008 |
20080201796 | Transformed plants accumulating mono-and/or sesquiterpenes - The present invention relates to plant expressing transgenes and to plants transformed to comprise additional copies of genes, said genes encoding at least a HMGR-CoA reductase and a terpene synthase. The invention further claims methods for preparing the plants, and a method for producing terpenes. The present thus provides a reliable and cost effective platform for generating any terpene, in particular any mono- and/or sesquiterpene of interest. For example, the skilled person may use any gene encoding a sesquiterpene synthase for accumulating the respective sesquiterpene in the plant of the present invention. | 08-21-2008 |